Multiple Myeloma News


Here are all the latest news articles written by The Beacon’s staff.

For news articles about treatments commonly given to myeloma patients, click on these links:
bisphosphonates, KyprolisPomalyst (Imnovid), Revlimid, thalidomide, Velcade, and Zometa.

For news articles about potential new myeloma treatments, click on these links:
ARRY-520 (filanesib), ACY-1215 (ricolinostat), afuresertib (GSK2110183), BT-062, daratumumab, elotuzumab, ixazomib (MLN9708),  marizomib (NPI-0052), MOR202, oprozomib, panobinostat, SAR650984, Treanda (bendamustine), and Zolinza (vorinostat).

For news articles about specific myeloma-related topics, click on these links:
bone disease, kidney failure, MGUS, maintenance therapy, peripheral neuropathysecondary cancer, smoldering multiple myeloma, and stem cell transplants.


[ by | Sep 3, 2014 7:39 am | 9 Comments ]
Dyclonine, The Active Ingredient In Sucrets, May Enhance The Anti-Myeloma Activity Of Velcade

Results of a small preclinical study conducted at the Karmanos Cancer Center in Detroit indicate that the oral anesthetic dyclonine may enhance the anti-myeloma activity of Velcade.

Dyclonine is the active ingredient in the Sucrets brand of sore throat lozenges, which are sold over-the-counter in drugstores and other retailers in Canada and the United States.  Sucrets lozenges are marketed by Insight Pharmaceuticals.

The Karmanos researchers conducted laboratory tests of dyclonine’s activity against the so-called “RPMI8226″ line of myeloma cells, which is commonly used in pre-clinical testing of potential myeloma therapies. …

Read the full story »
[ by | Aug 27, 2014 9:52 pm | 6 Comments ]
OncoPep Begins Sponsorship Of The Myeloma Beacon

OncoPep, a biotech company developing a potential therapeutic vaccine for multiple myeloma, is the Myeloma Beacon’s newest pharmaceutical industry sponsor.

OncoPep was founded in 2010 to develop novel cancer immunotherapies that stimulate a patient’s own immune system to attack cancer cells. The company’s first investigational immuno­therapy is PVX-410, a cancer vac­cine based on re­search in the laboratory of Dr. Kenneth Anderson and Dr. Nikhil Munshi at the Dana-Farber Cancer Institute in Boston.

“OncoPep’s decision to support The Myeloma Beacon is yet another ex­ample of a forward-looking organi­za­tion finding itself aligned …

Read the full story »
[ by | Aug 26, 2014 1:26 am | 2 Comments ]
MRI Of The Spine Identifies Smoldering Myeloma Patients At High Risk Of Progressing To Multiple Myeloma

A recently published Greek study provides updated data on the sig­nif­i­cance of MRI-detected focal lesions in the spine in patients with smol­der­ing myeloma.

The Greek study confirms that having more than one focal lesion in the spine puts a smoldering myeloma patient at a noticeably higher risk of progressing to multiple myeloma.

Focal lesions are areas of abnormal cells in the bone marrow. They are not lesions in the outer (hard) area of the bone – lesions which are often called “lytic” lesions.

The Greek researchers found that the smoldering …

Read the full story »